Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Spinifex Pharmaceuticals
Stamford, Connecticut, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Spinifex Pharmaceuticals developed EMA401, a first-in-class oral AT2R antagonist for chronic neuropathic pain. Positive Phase II results were published in The Lancet, showing efficacy in post-herpetic neuralgia without central nervous system side effects or serious adverse events. The company was acquired by Novartis for $200 million upfront plus milestones to further develop this approach to peripheral neuropathic pain treatment. Later reports indicate that development of EMA401 was discontinued due to liver toxicity observed during long-term dosing studies in primates.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (specifically angiotensin II type 2 receptor antagonists)
- Industry
- Biotech
02
Partnerships
No major pharma partnerships prior to acquisition; strong venture capital syndicate including Novo A/S and Canaan Partners.
Beyond the preview
Go deeper on Spinifex Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spinifex Pharmaceuticals.